Antihypertensive therapy: How to evaluate the benefits

American Journal of Cardiology

Volumn 79, Issue 10 A, 1997, Pages 3-8

  Zanchetti, Alberto ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFECT; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; PRIORITY JOURNAL;

ACTUARIAL ANALYSIS; ANTIHYPERTENSIVE AGENTS; COST-BENEFIT ANALYSIS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; RANDOMIZED CONTROLLED TRIALS; VALUE OF LIFE;

EID: 0030831203     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00264-6     Document Type: Conference Paper

References (26)

1. Fries ED. Organization of a long-term multiclinic therapeutic trial in hypertension. Gross F. Antihypertensive Therapy. Principles and Practice. 1966;345-354 Springer, Berlin.
2. Zanchetti A. Presidential lecture. Antihypertensive therapy: pride and prejudice. J Hypertens. 13:1995;1522-1528.
3. Collins R, Peto R, MacMahon S, Herbert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke and coronary heart disease. Part 2. Short term reduction in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet. 335:1990;827-838.
4. Collins R, Peto R. Antihypertensive drug therapy: effects on stroke and coronary heart disease. Swales JDM. Textbook of Hypertension. 1994;1156-1164 Blackwell Scientific, Oxford.
5. Moser M, Herbert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol. 27:1996;1214-1218.
6. Zanchetti A. What have we learned and what haven't we from clinical trials on hypertension? Laragh JH, Brenner BM. Hypertension: Physiology, Diagnosis and Management. 2nd Ed. 1995;2509-2529 Raven Press, New York.
7. Zanchetti A. Has antihypertensive treatment prevented vascular disease or vascular events? J Cardiovasc Pharmacol. 19:((suppl 3)):1992;S1-S5.
8. Zanchetti A. The antiatherogenic effects of antihypertensive drugs: experimental and clinical evidence. Clin Exp Hypertens. 4:1992;307-331.
9. Zanchetti A. Antiatherosclerotic effects of antihypertensive drugs: recent evidence and ongoing trials. Clin Exp Hypertens. 18:1996;489-499.
10. Zanchetti A. Trials investigating the antiatherosclerotic effects of antihypertensive drugs. J Hypertens. 14:((suppl 2)):1996;S77-S81.
11. Zanchetti A. Evaluating the benefits of an antihypertensive agent using trials based on events and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine Trial (SHELL) and the European Lacidipine Study on Atherosclerosis (ELSA) trials. J Hypertens. 13:((suppl 4)):1995;S35-S39.
12. Zanchetti A. Prevalence of carotid atherosclerosis in hypertension: preliminary baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). Blood Press. 5:((suppl 4)):1996;30-35.
13. Simpson FO. Guidelines for antihypertensive therapy: problems with a strategy based on absolute cardiovascular risk. J Hypertens. 14:1996;683-689.
14. MacMahon S. Guidelines for antihypertensive therapy. J Hypertens. 14:1996;691-693.
15. Swales JD. Treating hypertension. J Hypertens. 14:1996;813-814.
16. Zanchetti A, Mancia G. Benefits and cost-effectiveness of antihypertensive therapy. The actuarial versus the intervention trial approach. J Hypertens. 14:1996;809-811.
17. Strasser T. Inferences from drug trials: risks, probabilities, ethics, and decision taking. Strasser T, Ganten D. Mild Hypertension: From Drug Trials to Practice. 1987;77-83 Raven Press, New York.
18. 1993 Guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. J Hypertens. 11:1993;905-918.
19. Pyörälä K, De Baker G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J. 15:1994;1300-1331.
20. Guidelines for the Management of Mildly Raised Blood Pressure in New Zealand. 1995;Ministry of Health, Wellington.
21. The effect of treatment on mortality in "mild" hypertension. N Engl J Med. 307:1982;976-980.
22. Zanchetti A, Mancia G. Debating the value of absolute versus relative risk. J Hypertens. 14:1996;681.
23. Zanchetti A. Goals of antihypertensive treatment: prevention of cardiovascular events and prevention of organ damage. Blood Press. 1:1992;205-211.
24. Sytkowski PA, D'Agostino RB, Belanger AJ, Kannel WB. Secular trends in long-term sustained hypertension, long-term treatment, and cardiovascular mortality: the Framingham Heart Study 1950-1990. Circulation. 93:1996;697-703.
25. Blood Pressure: Insurance Experience and Its Implications. 1961;Metropolitan Life Insurance Company, New York.
26. Johannesson M. The cost-effectiveness of hypertension treatment in Sweden. Pharmacoeconomics. 7:1995;242-250.